Source comparison
Kisspeptin vs PT-141 — Comparison Table
Mechanism Binds GPR54 receptor → GnRH release → LH/FSH secretion → gonadal hormone production Activates MC3R/MC4R receptors in hypothalamus → direct CNS arousal independent of hormones Kisspeptin requires intact HPG axis; PT-141 bypasses it entirely Onset Time
This comparison does not assign a generated winner or score.
- Mechanism
- Binds GPR54 receptor → GnRH release → LH/FSH secretion → gonadal hormone production
- Activates MC3R/MC4R receptors in hypothalamus → direct CNS arousal independent of hormones
- Kisspeptin requires intact HPG axis; PT-141 bypasses it entirely
- Onset Time
- 60–120 minutes (hormonal cascade delay)
- 45–90 minutes (direct receptor activation)
- PT-141 acts faster due to CNS mechanism
- Primary Use
- Hypogonadotropic hypogonadism, hypothalamic amenorrhea, suppressed GnRH signaling
- Hypoactive sexual desire disorder (HSDD), psychogenic ED, CNS-mediated dysfunction
- Kisspeptin for hormonal restoration; PT-141 for CNS-mediated arousal
- Hormonal Dependency
- Requires functional pituitary and gonads
- Works regardless of testosterone, estradiol, or LH levels
- PT-141 effective even in primary gonadal failure
- Common Side Effects
- Injection site warmth, mild headache, flushing (5–10%)
- Nausea (40%), flushing (20%), headache (11%), transient BP elevation
- PT-141 has significantly higher GI and cardiovascular side effect rates
- FDA Approval Status
- Not FDA-approved (investigational peptide)
- FDA-approved for premenopausal women with HSDD (brand: Vyleesi)
- PT-141 is the only FDA-approved peptide for sexual dysfunction
- Typical Research Dose
- 0.3–4.0 nmol/kg IV or 1–2 mcg/kg subcutaneous
- 1.75 mg subcutaneous as needed (max 8 doses/month)
- Dosing protocols differ by 100× due to receptor affinity and pathway